“Grades” for FDA Approvals: When Academics Weigh in on Regulation
This article was originally published in RPM Report
Executive Summary
Physicians and patients need a better understanding of the quality of clinical trial design and data used to approve drugs, say researchers in a study published in JAMA. That led them to suggest a grading system to add another layer of information to FDA approvals, adding another academic suggestion for elaborating, explaining and embellishing FDA action.
You may also be interested in...
FDA/IoM “Uncertainty” Conference Adds Uncertainty to Biogen Growth Plans For Tysabri
An FDA/Institute of Medicine workshop on characterizing and communicating the uncertainty inherent in risk/benefit decisions touched on an important topic for every sponsor. But two “case studies” included points a very particular interest to Biogen Idec, and to sponsors in the COPD class.
Many Drug Approval Delays, Denials Could Be Prevented, FDA Study Shows
Agency reports preventable deficiencies, including failure to select optimal drug doses and suitable study endpoints, account for many drug rejections, approval delays.
Regressing to the Mean: FDA Innovative Drug Approvals Drop Back to “Normal” Levels
Last year’s 39 NME approvals is not the “new normal,” Office of New Drugs Director John Jenkins declares. FDA approved just 27 NMEs in 2013. The return to normal also included a quiet December.